Our most-read retinal coverage of 2025 highlights how higher-dose therapies and real-world evidence are refining treatment approaches for AMD and diabetic macular edema. From registry and global study data informing extended dosing intervals with aflibercept 8 mg to insights on the timing of anti-VEGF therapy around cataract surgery, these articles reflect continued progress toward more durable and individualized retinal care.
IRIS Registry data shows early aflibercept 8 mg use allows for 12-week injection intervals in AMD and DME cohorts
Diana Do, MD, of Stanford University, spoke with Ophthalmology 360 about a study that used IRIS Registry data to determine whether use of aflibercept 8 mg at the beginning of treatment for AMD or DME could improve outcomes and interval dosing.
Watch the full video here.
Real-world study offers early insights into aflibercept 8 mg for DME
Early real-world findings from the global SPECTRUM study suggest that aflibercept 8 mg is being effectively used in both treatment-naïve and previously treated patients with diabetic macular edema, with enrollment spanning 12 countries. Interim data highlight distinct baseline characteristics between cohorts, offering an early snapshot of how this higher-dose therapy is being applied across diverse DME populations in routine clinical practice.
Read the full article here.
Preoperative anti-VEGF therapy reduces swelling after cataract surgery in diabetic eye
Giving anti-VEGF injections 1 week before cataract surgery may better protect against postoperative macular swelling in patients with diabetic macular edema than treating at the time of surgery, according to a study. Among 4 diabetic patient groups, only those who received preoperative anti-VEGF avoided a significant postoperative increase in central macular thickness, with more stable macular measurements after surgery,highlighting the potential benefit of earlier intervention in DME patients undergoing cataract extraction.
Read the full article here.
Related Content
